The development of bispecific antibody drugs that simultaneously target inhibitory receptors/ligands and another inhibitory receptor or co-stimulatory receptor, by selectively targeting immune checkpoints to rescue T cell exhaustion, provides additional options for enhancing the anti-tumor ability of CD8+ T cells [214]. Here, CD8A is linked to neoplasm.